Merkel-cell polyomavirus (MCPyV) is rarely associated to B-chronic lymphocytic leukemia (1 out of 50) samples and occurs late in the natural history of the disease. J Clin Virol 2012;55(4):367-9.
. Mesenchymal stem cells display hepato-protective activity in lymphoma bearing xenografts. Invest New Drugs 2012;30(2):803-7.
. The negative prognostic value of TRAIL overexpression in oral squamous cell carcinomas does not preclude the potential therapeutic use of recombinant TRAIL. Invest New Drugs 2012;30(2):810-8.
. Potential role of TRAIL in the management of autoimmune diabetes mellitus. Curr Pharm Des 2012;18(35):5759-65.
. Simultaneous determination of multiple cytokines reveals a pro-inflammatory and pro-angiogenic signature after major cardiothoracic surgery: potential role of C-reactive protein. Cytokine 2012;60(3):593-5.
. SOCS1 is significantly up-regulated in Nutlin-3-treated p53wild-type B chronic lymphocytic leukemia (B-CLL) samples and shows an inverse correlation with miR-155. Invest New Drugs 2012;30(6):2403-6.
. Soluble TRAIL is elevated in recurrent miscarriage and inhibits the in vitro adhesion and migration of HTR8 trophoblastic cells. Hum Reprod 2012;27(10):2941-7.
. The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status. Haematologica 2012;97(11):1722-30.
. State of art and recent developments of anti-cancer strategies based on TRAIL. Recent Pat Anticancer Drug Discov 2012;7(2):207-17.
. TNF-related apoptosis-inducing ligand significantly attenuates metabolic abnormalities in high-fat-fed mice reducing adiposity and systemic inflammation. Clin Sci (Lond) 2012;123(9):547-55.
. TRAIL, a new weapon against neointimal hyperplasia. Cardiology 2012;123(2):94-6.
. .